在新诊断的多发性骨髓瘤中进行B细胞成熟抗原/CD19双向免疫治疗
Wanting Qiang1, Jing Lu1, Yanchun Jia1
1Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Shanghai, China.
JAMA oncology
|July 25, 2024
概括
GC012F是一种新型的仿真抗原受体 (CAR) T细胞疗法,在高风险的新诊断多发性骨髓瘤 (NDMM) 患者中显示出有前途的安全性和有效性,符合移植资格. 所有可评估的患者都获得了严格的完整反应和最小的残留疾病负面影响,表明改善结果的潜力.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 高风险的新诊断多发性骨髓瘤 (NDMM) 患者经常面临标准治疗的不良结果.
- 新型前线治疗对于改善这种患者群体的临床结果至关重要.
- GC012F是一种B细胞成熟抗原/CD19双向的CAR T细胞疗法,提供了一个潜在的新选择.
研究的目的:
- 评估GC012F在NDMM中的安全性,药理动力学,患者健康和生存结果.
- 探索GC012F作为一线治疗在可移植,高风险的NDMM患者的疗效.
主要方法:
- 一个单臂,开放标签的第一阶段队列研究.
- 招募了22名高风险NDMM可接受移植的患者.
- 患者接受了诱导疗法,随后以不断升级的剂量输注GC012F.
主要成果:
- GC012F表现出良好的安全性,没有神经毒性作用,可控的细胞因子释放综合征.
- 所有19名可评估的患者都获得了严格的完整反应和最小的残留疾病负面影响.
- 强大的CAR T细胞扩张和快速反应在不同剂量水平上被观察到.
结论:
- GC012F显示出作为高风险NDMM患者安全有效的前线治疗的潜力.
- 观察到的结果表明积极的健康和生存益处.
- 需要更大的队列和更长的随访时间来证实这些发现.
相关概念视频
01:24B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K
01:22T Cell Activation and Clonal Selection
694
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
694
01:27Tumor Immunotherapy
501
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
501
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:31Hybridoma Technology
14.4K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.4K